All-biologic Regimen Efficacious And Well-tolerated In Elderly Lung Cancer Patients, Fox Chase Cancer Center Study Suggests

ScienceDaily (Aug. 1, 2009) — Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported at the annual meeting of the International Association for the Study of Lung Cancer.